Myeloid-Derived Suppressor Cells Expressing Myeloperoxidase Directly Inhibit Adaptive Immune Cells Limiting Immunotherapy in Melanoma

Abstract

A recent breakthrough in treating melanoma patients is the use of immune checkpoint therapy (ICT). Unfortunately, the majority of patients do not respond to ICT. Complicating matters, is that as cancer develops, it can re-program immune cells to work in favor of tumor growth. One such population of cells are myeloid-derived suppressor cells (MDSCs). MDSCs dampen the immune system from recognizing cancer and decrease ICT treatment response. Preliminary data suggests that the enzyme myeloperoxidase is overexpressed in MDSCs. We hypothesize that by limiting the function of myeloperoxidase, we limit the effects of MDSCs to enable successful ICT response in melanoma.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2020
Accession Number
AD1135287

Entities

People

  • Tracy Liu

Organizations

  • The University of Texas MD Anderson Cancer Center

Tags

DTIC Thesaurus Topics

  • Allergy And Immunology
  • Blood
  • Cell Line
  • Cells
  • Cytokines
  • Governments
  • Immune System
  • Local Governments
  • Medical Personnel
  • Myeloid Cells
  • Neoplasms
  • Patent Applications
  • Professional Development
  • Students
  • Symposia
  • Therapy
  • Training

Fields of Study

  • Biology

Readers

  • Aerospace Propulsion Engineering.
  • Molecular Biology and Genetics
  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech